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Background: To better understand the mechanisms of the SDC1 expression in invasive ductal carcinoma, we
studied the correlations between SDC1 expression and related gene expressions (RSPO1, WNT1, WT1, and P16).
Methods: Using 100 cases of invasive ductal carcinoma tissue, we screened expressions of RSPO1, WNT1, WT1,
P16, and SDC1 using immunohistochemistry. We analyzed the association between the immunoreactivities and
clinicopathological parameters.
Results: WT1 expression was associated with tumor grade. RSPO1 expression was associated with progesterone
receptor expression. Expressions of RSPO1, WT1, and P16 were significantly associated with disease-free survival.
RSPO1 and P16 showed statistically significant hazard ratios. SDC1 ectodomain expression was significantly associated
only with P16 expression. Immunoreactivity of SDC1 cytoplasmic domain was associated with WT1 and WNT1.
However, WNT1 expression failed to show a significant association with disease-free survival.
Conclusions: RSPO1 and P16 immunoreactivity was found to be an independent prognostic indicator in invasive
ductal cancer. Cytoplasmic expression of SDC1 is positively correlated with tumor-prone proteins (WT1 and WNT1) and
membranous expression of SDC1 is positively correlated with the tumor suppressor (P16).
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Carcinoma of the breast, besides skin cancer, is the
most common malignancy in women and the number
of women with breast cancer is increasing [1]. Among
several histologic types of breast cancer, ductal carcinoma
is generally referred to as adenocarcinoma without other
designation and comprises the majority (79%) of breast
cancer [1]. Patient’s age, age at menarche, and estrogen
exposure are well known risk factors of breast cancer.
There is currently a constant search for molecular markers
to aid in the diagnosis of cancer and patient prognosis.
To date, several genes and their products have been
introduced to predict the prognosis of breast cancer
patients, such as transmembrane protease serine 4
(TMPRSS4) [2], c-Kit [3], and syndecan-1 (SDC1) [4].* Correspondence: suyoung@catholic.ac.kr
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stated.SDC1 is a member of the syndecan family, which is a
group of heparan sulfate proteoglycans (HSPGs); four
different types of syndecans are known in human [5].
The expression of HSPGs, including the core proteins
and glycosaminoglycan chains, is altered in malignant
tumors [6]. Among the syndecans, SDC1 is associated
with various human cancers, including breast cancer.
However, changes of SDC1 expression in tumors are not
straightforward. Generally, SDC1 expression is reduced in
most malignant tumors [7,8]. However, increased SDC1
expression has been reported in breast cancer [4] and
pancreatic cancer [9]. Out of 13 HSPGs, only SDC1 has
been shown as overexpressed in breast cancer [10].
In addition to quantitative changes in SDC1 expression,
cleavage of SDC1 core protein in malignancy has
been reported [6]. SDC1 consists of three domains; the
ectodomain, the transmembrane domain, and the cyto-
plasmic domain [5]. Cleavage and shedding of the
SDC1 ectodomain is found in multiple myeloma [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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in several cancers. In gastric cancer, patients with
SDC1-positive stroma had a worse outcome than patients
with SDC1-negative stroma [12]. In colorectal cancer,
SDC1 expression was associated with stage and grade
of cancer [13]. Loss of epithelial SDC1 was associated
with a more favorable prognosis in breast cancer [14]
and SDC1 overexpression was associated with poor
overall survival in estrogen receptor-negative patients
[4]. Strong stromal staining, which is not found in
normal breast tissue, was found in infiltrating ductal
carcinomas [15].
However, the association of SDC1 overexpression
with unfavorable prognosis is contradictory, with other
reports claiming that SDC1 loss promotes invasion and
metastasis and is associated with unfavorable outcome
[7,11]. Because SDC1 shedding itself increases SDC1
expression in the cell [16], cytoplasmic expression of
SDC1 may not represent the functional amount of
SDC1. On the contrary, increased cytoplasmic expression
may represent a lack of effective SDC1 on the cell
surface and a reactive change by the feedback mech-
anism. Therefore, the cytoplasmic expression of SDC1
may mislead the clinical significance of the SDC1
product. To clarify this possible ambiguity in terms of
clinical significance, a comparison of membranous and
cytoplasmic expression of SDC1 is needed; this may
resolve contradictory reports on the effects of SDC1
in tumor cells.
Although there are several reports showing an alter-
ation of SDC1 in human cancers, none of them clearly
explains the control mechanism or the effects of SDC1
expression. Considering that gene expression is affected
by many other related gene expressions, evaluation of
the gene expression associated with SDC1 may give us
a clue to understand the regulation mechanism or
affected pathways by SDC1 expression. According to
previous reports, several genes have been associated
with SDC1 expression. A strong correlation was reported
between SDC1 expression and WT1 [17], and HSPGs
have been shown to be necessary for the proper activity
of WNT proteins [18]. Syndecans are also known to
regulate WNT signaling. SDC1-null mice showed in-
hibition of mammary tumor development and WNT-
dependent tumor initiation [19]. R-spondin proteins and
P16 are closely related to the WNT/β-catenin pathway
[20]. By evaluating these associated proteins, the alter-
ation mechanism of SDC1 expression may be further
elucidated.
In this study, we evaluated the clinical significance
of SDC1 expression and that of the associated genes,
including WT1, RSPO1, WNT1, and P16. Also, we com-
pared several screening methods of SDC1 immunoreactivity
to find the most informative one.Methods
Patients and tumor samples
This study included tumor tissues surgically resected
from 100 patients who visited Uijeongbu Mary’s Hospital
and were diagnosed with invasive ductal carcinoma of
the breast between 2002 and 2004. Patients’ age ranged
between 29 and 77 (mean, 49.5) years old. All patients were
diagnosed as invasive ductal carcinoma; 43 cases received
adjuvant chemotherapy, 35 cases received hormone
therapy, and 21 cases received adjuvant radiotherapy.
Disease-free survival data (median, 62.8 months; range,
12.8 to 103.3 months) was available. The disease relapsed
in 19 patients and 6 patients died of the disease. Using
the tissues, tissue microarray blocks were constructed and
used for immunohistochemical staining. Human tissue
acquisition and its use followed the Institutional Review
Board-approved protocol (CUMC11U058) from the Cath-
olic University of Korea, School of Medicine.
Immunohistochemistry
The immunohistochemical staining of breast cancer tissue
followed the previously reported protocol [21]. Briefly,
tissue sections were transferred to ProbeOn Plus slides
(Fisher Scientific, Pittsburgh, PA, USA) and dried for 2
hours at 56°C in a drying oven (Agilent Technologies,
Santa Clara, CA, USA). The sections were deparaffi-
nized in xylene 3 times and rehydrated through 100%,
90%, 80%, and 70% ethanol and Tris-buffered saline
(pH 7.4). For antigen retrieval, the tissues were immersed
in 10 mM sodium citrate buffer (pH 6.0) and boiled in
a microwave for 20 minutes. After treating the tissues
with 3% hydrogen peroxide in phosphate buffered saline
to quench endogenous peroxidase, the tissues were in-
cubated with diluted primary antibody at 4°C overnight
(Table 1). After incubating the tissue with biotinylated
secondary antibody, the TSA HRP System (PerkinElmer,
Waltham, MA, USA) was used to amplify signal intensity.
For visualization, liquid DAB + substrate chromogen system
(Dako, Glostrup, Denmark) was used. Immunoreactivity
was classified according to the percentage of stained tumor
cells; strong positive, >50% of cells stained; weak positive,
10% to 50% of cells stained; negative, <10% of cells stained.
For SDC1, membranous staining and cytoplasmic staining
was scored separately for comparison. For RSPO1, WNT1,
and WT1, the cytoplasmic stain was counted. For P16,
the nuclear stain was scored.
Statistical analysis
Where appropriate, χ2 test or Fisher’s exact test were
used to evaluate association of immunoreactivity with
clinicopathologic features. For survival analysis, the Kaplan-
Meier method and the non-parametric log-rank test
were used. We used Cox’s multivariate proportional
hazard model to determine hazard ratios of selected
Table 1 The primary antibodies used in immunohistochemistry
Target Dilution factor Host Clone Provider
SDC1, ectodomain 1:40 Mouse monoclonal B-A38 Abcam, Cambridge, UK
SDC1, cytoplasmic domain 1:100 Rabbit polyclonal BioVision, Milpitas, USA
P16 1:10 Mouse monoclonal JC8 Santa Cruz Biotechnology, Dallas, USA
RSPO1 1:500 Rabbit polyclonal Abcam
WNT1 1:20 Rabbit polyclonal H-89 Santa Cruz Biotechnology
WT1 1:500 Rabbit polyclonal C-19 Santa Cruz Biotechnology
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foundation, Vienna, Austria) for statistical tests.
Results
Patient characteristics
Most of the cases studied consisted of grades II (52 cases)
and III (44 cases). The most frequent T stage was T2 (63
cases). There were 27 and 10 cases for T1 and T3 stages,
respectively. Nodal stage was N0 and N1 in 42 and 36
cases, respectively. Estrogen receptor was positive in 62
cases and progesterone receptor was positive in 67 cases
(Table 2).
SDC1 immunoreactivity
We used two different antibodies to detect different
domains of SDC1 in the tumor cells. Anti-SDC1e antibody
is directed against the ectodomain and anti-SDC1c anti-
body is against the cytoplasmic domain of the protein. ForTable 2 Patient pathological parameters







T stage T1 27
T2 63
T3 10




Estrogen receptor Negative 29
Positive 62
NA* 9
Progesterone receptor Negative 24
Positive 67
NA* 9
*NA: Not available.anti-SDC1e, a membranous stain was found in 29 cases
and a cytoplasmic stain was found in 64 cases; 30 cases
were negative for anti-SDC1e. For anti-SDC1c, a mem-
branous stain was found in 33 cases and a cytoplasmic
stain was found in 34 cases; 59 cases were negative for
anti-SDC1c (Figure 1). Estrogen receptor was significantly
associated with the membranous stain of anti-SDC1e
(Table 3).P16, RSPO1, WNT1, and WT1 expression
P16 was positive in 26 cases and RSPO1 was positive in
86 cases. WNT1 was positive in 70 cases and WT1 was
positive in 39 cases (Figure 1). WT1 was associated with
tumor grade (P = 0.025) and RSPO1 was associated with
progesterone receptor expression (P = 0.019) (Table 3). P16
expression was significantly associated with membranous
stain of anti-SDC1e (P = 0.008). The cytoplasmic stain of
anti-SDC1c was associated with WT1 (P = 0.007) and
WNT1 (P = 0.020) expressions (Table 4). RSPO1, WT1,
and P16 positivity showed a significant disease-free survival
difference between the positive group and the negative
group. WNT1 expression failed to show a disease-free
survival difference between the groups (Figure 2).
Multivariate analysis showed that RSPO1 and P16 ex-
pression were independent prognostic factors for dis-
ease-free survival (P = 0.029 and P = 0.027, respectively).
On the contrary, SDC1 failed to show a significant haz-
ard ratio (1.12, P = 0.841). Tumor grade, which is one of
the well-known prognostic factors of breast cancer,
showed a significant hazard ratio (4.48, P = 0.010) in our
data (Table 5).Discussion
SDC1 expression is a major research topic for various
human malignancies. Although immunohistochemistry
using tissue microarray material is a general screening
tool, the method of evaluating the immunoreactivity of
SDC1 has not been thoroughly verified. As far as we
know, all previous studies on SDC1 expression in tumor
cells by immunohistochemistry do not differentiate the
locations (the cytoplasmic membrane or the cytoplasm)
of SDC1 expression. Because SDC1 is a transmembrane
protein, elevated cytosolic expression may not directly
Figure 1 (See legend on next page.)
Choi et al. World Journal of Surgical Oncology 2013, 11:314 Page 4 of 9
http://www.wjso.com/content/11/1/314
(See figure on previous page.)
Figure 1 Representative SDC1, P16, RSPO1, WNT1, and WT1 expression in invasive ductal carcinoma of the breast by
immunohistochemistry. (A) Negative for ectodomain of SDC1. (B) Positive for ectodomain of SDC1. (C) Negative for cytoplasmic domain of
SDC1. (D) Positive for cytoplasmic domain of SDC1. (E) Negative for P16. (F) Positive for P16. (G) Negative for RSPO1. (H) Positive for RSPO1.
(I) Negative for WNT1. (J) Positive for WNT1. (K) Negative for WT1. (L) Positive for WT1.
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et al. reported that enzymatic degradation of the heparan
sulfate chains increased SDC1 shedding and that enhanced
SDC1shedding is accompanied by an increase in SDC1
expression [16]. Considering these findings, increased
cytosolic expression of SDC1 may paradoxically represent
a decrease in effective SDC1 protein on the cell surface or
mask decreased expression of SDC1 on the cell surface
when cytoplasmic and membranous expressions are
considered to be equivalent. This necessitates differential
scoring of SDC1 expression based on the location of
expression in immunohistochemistry.
SDC1 in malignant cells may have two different forms;
whole protein and remnant protein without ectodomain
by shedding. The ectodomain is frequently cleaved from
the SDC1 core protein in malignant cells. Removal of
heparan sulfate from the cell surface accelerates SDC1
shedding [22]. To evaluate the clinical significance of the
two different forms of SDC1, we used the antibodies for
both the ectodomain and the cytoplasmic domain. We
compared the two different scoring methods based on
the locations of SDC1 expression to find the most
informative way to evaluate SDC1 expression in tumor
cells. As a result, we found that membranous staining
by anti-SDC1e was associated with P16 expression.
This association is clinically significant, since we showed
the P16 expression is associated with disease-free survival.
In addition, the cytoplasmic stain of anti-SDC1c was
associated with WT1 and WNT1. Prognostic significance
was found in WT1 expression, but not in WNT1 expres-
sion. These findings suggest that the ectodomain and the
cytoplasmic domain of SDC1 may exert clinical effect
through p16- or WT1-dependent pathways, respectively.
Since the truncated form of SDC1, which is found in
multiple myeloma, does not have an ectodomain, bio-
logical effects of SDC1 on malignant behavior of tumor
cells may be dependent on the status of SDC1 size.
In the report claiming that loss of SDC1 was associated
with a more favorable prognosis, both cytoplasmic and
membranous patterns of SDC1 immunoreactivity were
counted [4]. Because SDC1 shedding causes increased
expression of SDC1 in the cytoplasm, immunoreactivity
by the cytoplasm alone or with membranous immuno-
reactivity may show poor patient survival. Considering
the molecular mechanism of SDC1, effective SDC1 scoring
should be based on membranous staining patterns.
The mechanisms of how SDC1 expression is altered
in tumor cells and the downstream pathways promotinginvasion and metastasis are not clearly understood.
One possible explanation can be found in the changes
of HSulf-1 in tumor cells. Besides alteration of the HSPG
core protein, alteration of heparan sulfate chains or
sulfonation patterns were also noted in human cancers
[23,24]. HSulfs, including HSulf-1, catalyze the desulfona-
tion on trisulfated disaccharides [25]. Decreased expression
of HSulf-1 stimulates cell growth by activation of the
EGFR-ERK pathway [26].
In this study, we showed that the immunoreactivity
of WT1, RSPO1, and P16 is significantly associated
with a more favorable disease-free survival. Further, we
also showed that RSPO1 and P16 are independent
prognostic factors by Cox’s multivariate proportional
hazard regression model. Tumor grade, which is a well-
known prognostic factor, was the most significant prog-
nostic factor in our model. P16 has also been introduced
as a prognostic marker by other investigators [27] and
we also confirmed the applicability in our data. In
addition to the well-known factors, we introduced RSPO1
as a prognostic marker.
R-spondin proteins are secreted agonists of the canonical
WNT/β-catenin signaling pathway [28]; there are four
different types of R-spondin [20]. The relationship be-
tween R-spondin proteins and cancer was introduced
in a study of RSPO1, whereby by regulating keratino-
cyte proliferation and differentiation, RSPO1 renders
keratinocytes prone to squamous cell carcinoma [29].
In normal breast tissue of healthy women, RSPO1 was
upregulated in the high serum estrogen level group
and downregulated in the breast cancer group [30].
Our results add the prognostic significance of RSPO1
to its previous association with breast cancer [30].
Although R-spondins are expected to act through β-
catenin stabilization and may synergize with WNT
proteins [28], the survival analysis grouped by WNT1
expression suggests that RSPO1 exerts a protective
effect through a pathway other than WNT1 signaling
in invasive ductal cancer.
Manipulation of proteoglycan function is under testing
for possible use to block cancer progression. A few glycos-
aminoglycan analogues, such as pentosan polysulfate and
suramin, have entered clinical trials [24]. However, severe
toxic effects prohibit the clinical use of these analogues.
The detail understanding of altered control mechanisms
of proteoglycans, such as SDC1, in tumor cells, will fa-
cilitate proteoglycan use in the diagnosis and treatment
of cancer patients.
Table 3 WNT1, WT1, RSPO1, P16, and SDC1 expression in invasive ductal carcinoma in relation to clinicopathological parameters (n = number of cases)
SDC1+ ** n SDC1-** n P value WNT1+ n WNT1- n P value WT1+ n WT1- n P value RSPO1+ n RSPO1- n P value P16+ n P16- n P value
T stage 0.087 0.201 0.073 1.000 0.346
1 11 13 22 5 15 11 22 1 9 16
2–3 18 55 48 25 24 45 64 5 17 55
N stage 0.111 0.171 0.482 0.237 1.000
0 16 24 33 9 19 22 38 1 11 29
1–3 13 44 37 21 20 34 48 5 15 42
Grade 0.052 0.147 0.025* 0.694 0.911
1–2 21 33 43 13 28 26 48 4 14 41
3 8 35 27 17 11 30 38 2 12 30
Estrogen 0.035* 0.442 0.577 0.643 0.104
receptor 45 17 25 34 55 3 13 48
Positive 14 47 18 11 9 18 24 2 11 16
Negative 13 14
Progesterone 0.124 0.276 0.545 0.019* 1.000
receptor 49 18 27 37 60 1 18 47
Positive 23 42 14 10 7 15 19 4 6 17
Negative 4 19
*P <0.05.



















Table 4 Association between SDC1 scoring methods and P16, WT1, WNT1, and RSPO1 expressions
P16+ n P16- n P value WT1+ n WT1- n P value WNT1+ n WNT1- n P value RSPO1+ n RSPO1- n P value
Membranous stain of SDC1e 0.008** 0.863 0.944 0.405
Positive 11 10 7 13 15 5 33 1
Negative 16 63 31 46 54 22 52 5
Cytoplasmic stain of SDC1e 0.724 0.998 0.254 0.405
Positive 9 29 15 22 32 6 33 1
Negative 18 44 23 37 41 16 52 5
Membranous stain of SDC1c 0.684 0.250 1.000 1.000
Positive 3 5 1 7 6 2 8 0
Negative 23 60 32 48 60 24 74 6
Cytoplasmic stain of SDC1c 0.605 0.007** 0.020* 0.410
Positive 11 22 18 13 29 4 31 1
Negative 15 43 15 42 37 22 51 5
SDC1e: SDC1 ectodomain.





















Figure 2 Survival analysis between groups showing different amount of expression of (A) RSPO1, (B) WT1, (C) P16, and (D)
WNT1, respectively.
Table 5 Prognostic factors for disease-free survival
selected by Cox’s multivariate proportional hazard
regression model
Hazard ratio 95% confidence interval Cox’s test P value
SDC1 1.12 0.36–3.56 0.841
Grade 4.48 1.43–14.01 0.010**
WNT1 0.87 0.33–2.31 0.779
WT1 0.90 0.27–2.99 0.862
RSPO1 0.16 0.03–0.83 0.029*
P16 0.10 0.01–0.77 0.027*
*P <0.05, **P <0.01.
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In summary, we presented the association of SDC1 and
related gene expressions by immunohistochemistry. The
cellular compartment and target domain need to be
mentioned in screening of SDC1 immunoreactivity. We
confirmed the prognostic significance of P16 as previously
suggested and newly introduced RSPO1 as a potential
prognostic marker in invasive ductal cancer of the
breast. Further, we showed P16 and WT1 expressions
to be associated with the ectodomain and the cytoplasmic
domain of SDC1 expression, respectively, with clinical
significance. Because P16 and WT1 have opposite
Choi et al. World Journal of Surgical Oncology 2013, 11:314 Page 9 of 9
http://www.wjso.com/content/11/1/314biological behaviors in tumorigenesis, screening of
SDC1 expression by immunohistochemistry requires a
clear description on expression location in the cell and
the protein target domain.
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